Business
PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials
HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical
About this update from Prf Technologies Ltd.
[{"type":"text","content":"HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) (\"PainReform\" or the \"Company\"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain. Upon completion of the Phase 3 studies, if successful, the Company plans to apply for a New Drug Approval for the management of post-operative pain.Based on extensive toxicology and pharmacokinetic studies, as well as positive Phase 2 results, the FDA has granted the Company an IND for PRF-110 and approved the initiation of Phase 3 trials for the treatment of post-operative pain. Unlike many drug trials that take months to years to complete, which are complex and whose endpoints are difficult to interpret, the planned trials are expected to last for a brief number of days with a one-month follow-up, with primary endpoints based on measurement on the familiar scale of 1 (no pain) to 10 (worst imaginable pain).PRF-110 is a viscous, waterless, clear oil-based solution that is instilled (deposited) directly into the surgical wound to provide localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated. The solution allows for ease of administration by the surgeon.Key attributes of PRF-100 include:PRF-110 is highly viscous and thus stays in place when administered into a surgical wound bed covering the inner surface of the surgical wound.PRF-110 remains within the surgical site when the wound is closed, without toxicity or proinflammatory effects.PRF-110 is easy to administer and its use is consistent with current surgical practice.PRF-110, being a solution, is highly uniform, resulting in consistent and sustained/extended release of the analgesic.Ropivacaine, the active drug used in PRF-110, is a safe and well-characterized local anesthetic.The components that make up the remainder of the PRF-110 formulation are classified as GRAS (Generally Regarded As Safe) by the FDA.Dr. Ehud Geller, the Chairman of the Board of the Company commented, \"Following the successful completion of our initial public offering for gross proceeds of $20 mil...